Compounds > adamantane
Page last updated: 2024-08-21

adamantane and Astrocytoma, Grade IV

adamantane has been researched along with Astrocytoma, Grade IV in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's0 (0.00)24.3611
2020's3 (60.00)2.80

Authors

AuthorsStudies
Defant, A; Mancini, I; Pancher, M; Quattrone, A; Rosatti, EF; Sidarovich, V; Sighel, D; Vigna, J1
Drill, M; Drummond, KJ; Galea, E; Hunn, M; Jayakrishnan, PC; Kan, LK; Monif, M; O'Brien, TJ; Sanfilippo, PG; Sequeira, RP; Todaro, M; Williams, DA1
Drill, M; Hamilton, JA; Jones, NC; Kan, LK; Monif, M; O'Brien, TJ; Powell, KL1
Avramis, IA; Avramis, VI; Christodoulopoulos, G; Gonzalez-Gomez, I; Laug, WE; McNamara, G; Sausville, EA; Suzuki, A1
Ban, K; Chandra, J; Gao, S; Long, J; Manchandia, T; Miller, C1

Other Studies

5 other study(ies) available for adamantane and Astrocytoma, Grade IV

ArticleYear
Expanding the Chemical Space of Arsenicin A-C Related Polyarsenicals and Evaluation of Some Analogs as Inhibitors of Glioblastoma Stem Cell Growth.
    Marine drugs, 2023, Mar-17, Volume: 21, Issue:3

    Topics: Adamantane; Arsenic Trioxide; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Stem Cells

2023
P2X7 receptor antagonism by AZ10606120 significantly reduced in vitro tumour growth in human glioblastoma.
    Scientific reports, 2023, 05-24, Volume: 13, Issue:1

    Topics: Adamantane; Aminoquinolines; Glioblastoma; Humans; Purinergic P2X Receptor Antagonists; Receptors, Purinergic P2X7; Temozolomide; Tumor Microenvironment

2023
Inhibition of purinergic P2X receptor 7 (P2X7R) decreases granulocyte-macrophage colony-stimulating factor (GM-CSF) expression in U251 glioblastoma cells.
    Scientific reports, 2020, 09-09, Volume: 10, Issue:1

    Topics: Adamantane; Aminoquinolines; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glioblastoma; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Purinergic P2X Receptor Antagonists; Receptors, Purinergic P2X7

2020
In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines.
    Cancer chemotherapy and pharmacology, 2002, Volume: 50, Issue:6

    Topics: Adamantane; Animals; Blotting, Western; Brain Neoplasms; Caspase 3; Caspases; DNA, Neoplasm; Drug Resistance, Neoplasm; Endothelial Growth Factors; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Extracellular Matrix Proteins; Female; Fusion Proteins, bcr-abl; Glioblastoma; Humans; Hydroquinones; In Vitro Techniques; Intercellular Signaling Peptides and Proteins; Leukemia, T-Cell; Lymphokines; Mice; Mice, Nude; Myosin Heavy Chains; Neoplasm Transplantation; Nonmuscle Myosin Type IIB; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factors

2002
Adaphostin cytoxicity in glioblastoma cells is ROS-dependent and is accompanied by upregulation of heme oxygenase-1.
    Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:4

    Topics: Adamantane; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; DNA Fragmentation; Fusion Proteins, bcr-abl; Glioblastoma; Glutathione; Heme Oxygenase-1; Humans; Hydroquinones; Reactive Oxygen Species; RNA, Messenger; Up-Regulation

2007